ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

DCE Recompetition Of Human Tissue Procurement Approved

November 23, 1990

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

HHS Agency Says It Has No Jurisdiction And No Cause to Act on I-ELCAP Allegations

March 2, 2012

How Bypass Budget Says NCI Will Spend Its FY 1984 Money

July 16, 1982

Four New DCCP Abs Established Without New Slots, More Money

January 15, 1982

Public Forum On NRSA Tuition Policies

April 14, 1995